FrostPharma is proud and pleased to announce that the company has been successful in the tender bidding process in Norway. The company has been notified of winning two national tender contracts in two different therapeutic areas, starting Feb 1, 2022 and running for two years with option to prolong another two years. This means that the health care providers and patients eligible for these specific treatments will have access to our value-added products throughout the tender contract period in Norway. The therapeutic areas in scope for these two treatments are sedation and anti-thrombotic treatment.
